Scisparc celebrates major breakthrough: positive results show its treatment has a remarkable impact on alzheimer's agitation

Phase iia trial outcome indicates the potential for a new way to help alzheimer's patients' agitation tel-aviv, nov. 15, 2023 (globe newswire) -- scisparc ltd. (nasdaq: sprc), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the “company” or “scisparc”), unveiled positive topline results from its investigator-initiated phase iia trial at the sophie & abraham stuchynski israeli alzheimer's medical center (imca).
SPRC Ratings Summary
SPRC Quant Ranking